ABIOMED

ABIOMED FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of ABIOMED (ABMD) as of Nov 6, 2026 is 182.87 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.08 % — a change of 86.45% (higher).

FCF Conversion

182.87 %

YoY

86.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ABIOMED is 2022 182.87 % . FCF Conversion Rate (FCF/EBITDA) of ABIOMED was 2021 98.08 % . It decreases by 86.45% higher compared to the previous year.

The ABIOMED FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
33.51 USD
Jan 1, 2016
160.36 USD
Jan 1, 2017
124.15 USD
Jan 1, 2018
121.85 USD
Jan 1, 2019
80.38 USD
Jan 1, 2020
133.45 USD
Jan 1, 2021
98.08 USD
Jan 1, 2022
182.87 USD
The ABIOMED FCF Conversion history
YEARFCF ConversionYoY
182.87 %+86.45%
98.08 %-26.50%
133.45 %+66.03%
80.38 %-34.04%
121.85 %-1.85%
124.15 %-22.58%
160.36 %+378.47%
33.51 %-88.10%
281.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABIOMED Stock analysis

What does ABIOMED do? Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ABIOMED stock

FCF Conversion Rate (FCF/EBITDA) of ABIOMED is 182.87 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of ABIOMED changed from 98.08 % to 182.87 %, representing a 86.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ABIOMED since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ABIOMED with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ABIOMED

All Key Metrics — ABIOMED